ReviewChest2019
Past, Present, and Future Research on the Lung Microbiome in Inflammatory Airway Disease.
Review in Chest, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Probiotic in the prevention of ventilator-associated pneumonia in critically ill patients: evidence from meta-analysis and trial sequential analysis of randomized clinical trials.BMC pulmonary medicine · 2022Pooled it
- Vitamin D supplementation in chronic obstructive pulmonary disease patients with low serum vitamin D: a randomized controlled trial.The American journal of clinical nutrition · 2022Trial
- Platycodon grandiflorum and Glycyrrhiza uralensis extract attenuates cyclophosphamide-induced tracheal mucosal barrier injury in broilers by modulating gut microbiota and short-chain fatty acids.Poultry science · 2026Article
- Asthma endotypes and theratypes.Chinese medical journal pulmonary and critical care medicine · 2026Review
- The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.Frontiers in immunology · 2026Review
- The Role of the Oral Microbiome and Dental Caries in Respiratory Health: A Systematic Review.Journal of clinical medicine · 2025Review
- Amelioration of Inflammation in Rats with Experimentally Induced Asthma byInternational journal of molecular sciences · 2024Article
- Microbiome and metabolome patterns after lung transplantation reflect underlying disease and chronic lung allograft dysfunction.Microbiome · 2024Article
- A metagenomic next-generation sequencing (mNGS)-based analysis of bronchoalveolar lavage samples in patients with an acute exacerbation of chronic obstructive pulmonary disease.Journal of molecular histology · 2024Article
- Comparison of the upper and lower airway microbiome in early postoperative lung transplant recipients.Microbiology spectrum · 2024Article
- Cross-domain microbiomes: the interaction of gut, lung and environmental microbiota in asthma pathogenesis.Frontiers in nutrition · 2024Review
- Characterization of the lung microbiome and inflammatory cytokine levels in women exposed to environmental risk factors: A pilot study.Immunity, inflammation and disease · 2023Article
- The Lung Microbiome: A New Frontier for Lung and Brain Disease.International journal of molecular sciences · 2023Review
- Analysis of sputum microbial metagenome in COPD based on exacerbation frequency and lung function: a case control study.Respiratory research · 2022Article
- Alterations in the respiratory tract microbiome in COVID-19: current observations and potential significance.Microbiome · 2022Review
- Impact of Lung Microbiota on COPD.Biomedicines · 2022Review
- Sputum Microbiota in Coal Workers Diagnosed with Pneumoconiosis as Revealed by 16S rRNA Gene Sequencing.Life (Basel, Switzerland) · 2022Article
- The lung microbiome in HIV-positive patients with active pulmonary tuberculosis.Scientific reports · 2022Article
- Decalogue for the selection of oral antibiotics for lower respiratory tract infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Exploring the Change of Host and Microorganism in Chronic Obstructive Pulmonary Disease Patients Based on Metagenomic and Metatranscriptomic Sequencing.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
COPD, asthma, and cystic fibrosis (CF) are obstructive lung diseases with distinct pathophysiologies and clinical phenotypes. In this paper, we highlight recent advances in our understanding of relationships between clinical phenotypes, host inflammatory response, and lung microbiota in these diseases. Although COPD, asthma, and CF largely have distinct lung microbiota and inflammatory profiles, certain commonalities exist. In all three of these lung diseases, and in healthy persons, anaerobic taxa that are typically associated with oral microbiota (eg, Prevotella species, Veillonella species) are present in the airways and associated with increased host inflammatory response. Similarly, across all three diseases, members of the Proteobacteria phylum are associated with more advanced disease. Finally, we highlight challenges in translating these findings into advances in clinical care, including continued knowledge gaps regarding the causal relationships between host inflammatory response, lung microbiota, medication effects, and clinical phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.